CN115279767A - 作为乙肝表面抗原抑制剂的四环化合物 - Google Patents

作为乙肝表面抗原抑制剂的四环化合物 Download PDF

Info

Publication number
CN115279767A
CN115279767A CN202180020995.6A CN202180020995A CN115279767A CN 115279767 A CN115279767 A CN 115279767A CN 202180020995 A CN202180020995 A CN 202180020995A CN 115279767 A CN115279767 A CN 115279767A
Authority
CN
China
Prior art keywords
alkyl
compound
radical
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020995.6A
Other languages
English (en)
Inventor
张寅生
敖汪伟
徐斌
吴杰
葛兴枫
徐宏江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN115279767A publication Critical patent/CN115279767A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本申请属于医药化学领域，涉及作为乙肝表面抗原抑制剂的四环化合物。本申请具体涉及式I化合物、其立体异构体、其药学上可接受的盐，其制备方法，含有该化合物的药物组合物，及其作为治疗乙型肝炎病毒感染的药物的用途。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202180020995.6A 2020-04-10 2021-04-09 作为乙肝表面抗原抑制剂的四环化合物 Pending CN115279767A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010278452 2020-04-10
CN2020102784521 2020-04-10
CN2020112600346 2020-11-12
CN2020112625697 2020-11-12
CN202011262569 2020-11-12
CN202011260034 2020-11-12
PCT/CN2021/086181 WO2021204252A1 (zh) 2020-04-10 2021-04-09 作为乙肝表面抗原抑制剂的四环化合物

Publications (1)

Publication Number Publication Date
CN115279767A true CN115279767A (zh) 2022-11-01

Family

ID=78022708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020995.6A Pending CN115279767A (zh) 2020-04-10 2021-04-09 作为乙肝表面抗原抑制剂的四环化合物

Country Status (2)

Country Link
CN (1) CN115279767A (zh)
WO (1) WO2021204252A1 (zh)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107759585A (zh) * 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
CN108727378A (zh) * 2017-04-19 2018-11-02 银杏树药业(苏州)有限公司 新型异喹啉类化合物及其医药用途
EP3856740A4 (en) * 2018-09-30 2021-12-15 Sunshine Lake Pharma Co., Ltd. CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

Also Published As

Publication number Publication date
WO2021204252A1 (zh) 2021-10-14

Similar Documents

Publication Publication Date Title
KR20230095878A (ko) 인을 함유하는 sos1 억제제
KR20170137165A (ko) 인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘
CN114555574B (zh) 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物
KR102658095B1 (ko) 안드로겐 수용체 길항제로서 다이아릴티오하이단토인 화합물
CN111315744B (zh) 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
CN113365999B (zh) 含有吡咯并杂环的衣壳蛋白装配抑制剂
AU2020251621A1 (en) Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
AU2021341258A1 (en) CD73 inhibitor and application thereof in medicine
KR102325454B1 (ko) 방사성표지화를 위한 방법 및 시약
CN116761603A (zh) 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途
JP2022500476A (ja) 環状ジヌクレオチド類似体、その医薬組成物及び使用
CN117377675A (zh) 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
CN113316575B (zh) 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
CN111918870B (zh) 氘代的低聚核苷酸及前体药物
CN115279767A (zh) 作为乙肝表面抗原抑制剂的四环化合物
CN111848678A (zh) 含磷类噻吩并嘧啶衍生物
CN115557968A (zh) 稠四环类化合物、其制备方法及其在医药上的应用
CN116669740A (zh) 嘧啶并吡啶类化合物及其制备方法和医药用途
CN117486876A (zh) 作为Akt激酶抑制剂的化合物
CN116547276A (zh) 含酰胺基和杂环烷基的tyk2抑制剂化合物
CN116783178A (zh) 含联环的tyk2抑制剂化合物
CN114907326A (zh) 含酰胺基和联环的tyk2抑制剂化合物
RU2768451C1 (ru) Селективный антагонист рецепторов типа A2A
CN115279762A (zh) 作为乙肝表面抗原抑制剂的氮杂双环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination